Jefferies London: Affinity Asset Advisors' Patrick Nosker shares a public investor's perspective on biotech and comments on a few of his firm's top positions
He describes getting through the last few years and how he thinks about 2026. Plus, comments on Xenon, Madrigal, and Alkermes.
Brought to you by










.png)